It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

BioNTech

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'

World / Science & Health Nov 19, 2020

Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'

Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.

How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine

World / Science & Health | FOCUS Nov 18, 2020

How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine

by Michael Erman and Julie Steenhuysen

Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.

Here’s to the immigrant heroes behind the BioNTech vaccine

Commentary / World Nov 15, 2020

Here’s to the immigrant heroes behind the BioNTech vaccine

by Andreas Kluth

Their journey as Turkish Germans cannot have been easy. Discrimination, overt or subtle, is rife in German society.

What happens to the other COVID-19 vaccines now?

Commentary / World Nov 13, 2020

What happens to the other COVID-19 vaccines now?

by Faye Flam

If the vaccine created by Pfizer and partner BioNTech fails to live up to its promise, will any slower but better competitors have a chance?

Pfizer COVID-19 vaccine trial reports no major safety issues

World / Science & Health Sep 16, 2020

Pfizer COVID-19 vaccine trial reports no major safety issues

Safety has been a paramount concern since AstraZeneca paused tests of the vaccine it's co-developing with the University of Oxford following an adverse event in a U.K.

Japan and AstraZeneca set for deal on 100 million doses of virus vaccine

National / Science & Health Aug 7, 2020

Japan and AstraZeneca set for deal on 100 million doses of virus vaccine

The drugmaker is expected to begin clinical trials in Japan later this month to confirm the efficacy and safety of its vaccine, currently being tested overseas.

Japan and Pfizer reach COVID-19 vaccine deal to treat 60 million people

National / Science & Health Aug 1, 2020

Japan and Pfizer reach COVID-19 vaccine deal to treat 60 million people

The agreement marks Japan's first advance deal for a vaccine to fight the coronavirus.

Pfizer and BioNTech coronavirus vaccine candidates on FDA fast track

Business / Corporate Jul 14, 2020

Pfizer and BioNTech coronavirus vaccine candidates on FDA fast track

The U.S.-listed shares of the German firm climbed about 15 percent, while Pfizer's stock rose about 5 percent.

« 1 2 3
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times